In vivo evolution of env in SHIV-AD8EO-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig.

IF 12 1区 医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Molecular Therapy Pub Date : 2025-02-05 Epub Date: 2024-12-12 DOI:10.1016/j.ymthe.2024.12.015
Daniel O'Hagan, Siddhartha Shandilya, Lincoln J Hopkins, Patricia A Hahn, Sebastian P Fuchs, José M Martinez-Navio, Michael D Alpert, Mathew R Gardner, Ronald C Desrosiers, Guangping Gao, Jeffrey D Lifson, Michael Farzan, Amir Ardeshir, Mauricio A Martins
{"title":"In vivo evolution of env in SHIV-AD8<sub>EO</sub>-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig.","authors":"Daniel O'Hagan, Siddhartha Shandilya, Lincoln J Hopkins, Patricia A Hahn, Sebastian P Fuchs, José M Martinez-Navio, Michael D Alpert, Mathew R Gardner, Ronald C Desrosiers, Guangping Gao, Jeffrey D Lifson, Michael Farzan, Amir Ardeshir, Mauricio A Martins","doi":"10.1016/j.ymthe.2024.12.015","DOIUrl":null,"url":null,"abstract":"<p><p>eCD4-immunoglobulin (Ig) is an HIV entry inhibitor that mimics the engagement of both CD4 and CCR5 with the HIV envelope (Env) protein, a property that imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in SHIV-AD8<sub>EO</sub>-infected rhesus macaques (RMs) treated with adeno-associated virus vectors encoding eCD4-Ig. In one RM, setpoint viremia plateaued at 1,000 vRNA copies/mL, despite concomitant serum concentrations of eCD4-Ig in the 60-110 μg/mL range, implying that the virus had gained partial eCD4-Ig resistance. Env mutations occurring prominently in this animal were cloned and further characterized. Three of these mutations (R315G, A436T, and G471E) were sufficient to confer substantial resistance to eCD4-Ig-mediated neutralization onto the parental Env, accompanied by a marked loss of viral fitness. This resistance was not driven by decreased CD4 affinity, subverted sulfopeptide mimicry, changes to co-receptor tropism, or by a gain of CD4 independence. Rather, our data argue that the Env evolving in this animal attained eCD4-Ig resistance by decreasing triggerability, stabilizing the triggered state, and changing the nature of its relationship to the host CD4.</p>","PeriodicalId":19020,"journal":{"name":"Molecular Therapy","volume":" ","pages":"560-579"},"PeriodicalIF":12.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11853013/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ymthe.2024.12.015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

eCD4-immunoglobulin (Ig) is an HIV entry inhibitor that mimics the engagement of both CD4 and CCR5 with the HIV envelope (Env) protein, a property that imbues it with remarkable potency and breadth. However, env is exceptionally genetically malleable and can evolve to escape a wide variety of entry inhibitors. Here we document the evolution of partial eCD4-Ig resistance in SHIV-AD8EO-infected rhesus macaques (RMs) treated with adeno-associated virus vectors encoding eCD4-Ig. In one RM, setpoint viremia plateaued at 1,000 vRNA copies/mL, despite concomitant serum concentrations of eCD4-Ig in the 60-110 μg/mL range, implying that the virus had gained partial eCD4-Ig resistance. Env mutations occurring prominently in this animal were cloned and further characterized. Three of these mutations (R315G, A436T, and G471E) were sufficient to confer substantial resistance to eCD4-Ig-mediated neutralization onto the parental Env, accompanied by a marked loss of viral fitness. This resistance was not driven by decreased CD4 affinity, subverted sulfopeptide mimicry, changes to co-receptor tropism, or by a gain of CD4 independence. Rather, our data argue that the Env evolving in this animal attained eCD4-Ig resistance by decreasing triggerability, stabilizing the triggered state, and changing the nature of its relationship to the host CD4.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过 AAV 传播 eCD4-Ig 后,SHIV-AD8EO 感染的猕猴体内 env 的演变。
eCD4-Ig 是一种人类免疫缺陷病毒(HIV)进入抑制剂,它模仿 CD4 和 CCR5 与 HIV 包膜(Env)蛋白的接合,这一特性使其具有显著的效力和广泛性。然而,Env 在遗传学上具有极强的可塑性,可以进化以逃避各种进入抑制剂。在这里,我们记录了用编码 eCD4-Ig 的腺相关载体(AAV)治疗猿-HIV(SHIV)-AD8EO 感染的猕猴(RMs)部分 eCD4-Ig 抗性的进化过程。在一只猕猴体内,尽管同时血清中的 eCD4-Ig 浓度在 60-110 μg/ml 范围内,但设定值病毒血症却稳定在 1,000 vRNA 拷贝/ml,这意味着病毒已获得部分 eCD4-Ig 抗性。我们克隆并进一步鉴定了在这种动物身上出现的Env突变。其中三个突变(R315G、A436T、G471E)足以使病毒对 eCD4-Ig 介导的亲本 Env 中和产生实质性抗性,并伴有明显的病毒适应性丧失。这种抗性并非由 CD4 亲和力下降、硫肽拟态被颠覆、核心受体趋向性改变或 CD4 独立性增强所驱动。相反,我们的数据表明,在这种动物体内进化的 Env 是通过降低触发性、稳定状态-2 以及改变其与宿主 CD4 关系的性质而获得 eCD4-Ig 抗性的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Molecular Therapy
Molecular Therapy 医学-生物工程与应用微生物
CiteScore
19.20
自引率
3.20%
发文量
357
审稿时长
3 months
期刊介绍: Molecular Therapy is the leading journal for research in gene transfer, vector development, stem cell manipulation, and therapeutic interventions. It covers a broad spectrum of topics including genetic and acquired disease correction, vaccine development, pre-clinical validation, safety/efficacy studies, and clinical trials. With a focus on advancing genetics, medicine, and biotechnology, Molecular Therapy publishes peer-reviewed research, reviews, and commentaries to showcase the latest advancements in the field. With an impressive impact factor of 12.4 in 2022, it continues to attract top-tier contributions.
期刊最新文献
Integrated Stress Response Promotes Acute Liver Failure by Activating SETD7 and Enhancing NLRP3 Methylation. Safety and Efficacy of Hemobeglogene Autotemcel (Hemo-cel) Gene Therapy in Five Patients with Transfusion-Dependent β-Thalassemia. Reprogramming CD22 CAR-T cells in vivo Using CD8-Targeted mRNA-LNPs to Treat Hematological Malignancies. Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion. Helper-dependent adenoviral vector-mediated expression of an LDL receptor/transferrin chimeric protein in muscle safely reduces atherosclerosis in LDLR-deficient mice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1